(IRTC) iRhythm Technologies - Ratings and Ratios
Patch Monitor, Monitoring Service, ECG Software, Gateway
IRTC EPS (Earnings per Share)
IRTC Revenue
Description: IRTC iRhythm Technologies
iRhythm Technologies Inc (NASDAQ:IRTC) is a digital healthcare company specializing in ambulatory cardiac monitoring services, primarily in the United States. The companys flagship product is the Zio ambulatory cardiac monitoring system, which includes various iterations such as Zio Monitor System, Zio XT System, and Zio AT System. These systems are prescription-only remote electrocardiogram (ECG) monitoring devices that record heart activity continuously for up to 14 days.
From a business perspective, iRhythms revenue growth is a key performance indicator (KPI). With a strong presence in the US market, the companys ability to expand its customer base and increase sales of its Zio monitoring systems will be crucial. Another important metric is the average revenue per user (ARPU), which can indicate the companys pricing power and ability to upsell or cross-sell its services. Additionally, the companys partnerships, such as its development collaboration agreement with Verily Life Sciences LLC, can be a significant driver of growth and innovation.
Analyzing iRhythms financials, we can observe that the company has a market capitalization of approximately $4.34 billion. The lack of a reported P/E ratio is not surprising, given the companys negative return on equity (RoE) of -112.84%. This suggests that iRhythm is currently unprofitable, which is not uncommon for growth-stage companies in the healthcare technology space. To gauge the companys financial health, we can examine its cash burn rate, operating expenses, and revenue growth rate. These metrics will be essential in determining iRhythms ability to achieve profitability in the future.
From a trading perspective, iRhythms stock has shown significant volatility, with an average true range (ATR) of 3.76, representing a 2.80% daily price movement. The stock is currently trading near its support and resistance levels, with key resistance levels at $153.8, $147.9, and $140.1, and support levels at $105.9, $98.5, and $87.4. A break above or below these levels could indicate a significant shift in the stocks price action.
IRTC Stock Overview
| Market Cap in USD | 5,673m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2016-10-20 |
IRTC Stock Ratings
| Growth Rating | 47.6% |
| Fundamental | 38.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 103% |
| Analyst Rating | 4.62 of 5 |
IRTC Dividends
Currently no dividends paidIRTC Growth Ratios
| Growth Correlation 3m | 80% |
| Growth Correlation 12m | 93.6% |
| Growth Correlation 5y | -15.5% |
| CAGR 5y | 9.24% |
| CAGR/Max DD 3y | 0.16 |
| CAGR/Mean DD 3y | 0.37 |
| Sharpe Ratio 12m | 1.02 |
| Alpha | 0.00 |
| Beta | 0.960 |
| Volatility | 41.05% |
| Current Volume | 311.2k |
| Average Volume 20d | 351.5k |
| Stop Loss | 166.7 (-3.2%) |
| Signal | -0.37 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-92.4m TTM) > 0 and > 6% of Revenue (6% = 39.4m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 12.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 80.90% (prev 107.9%; Δ -27.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 63.3m > Net Income -92.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (31.6m) change vs 12m ago 1.43% (target <= -2.0% for YES) |
| Gross Margin 69.78% (prev 67.19%; Δ 2.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.80% (prev 58.43%; Δ 11.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.90 (EBITDA TTM -65.4m / Interest Expense TTM 12.4m) >= 6 (WARN >= 3) |
Altman Z'' -0.69
| (A) 0.55 = (Total Current Assets 663.9m - Total Current Liabilities 132.2m) / Total Assets 964.0m |
| (B) -0.83 = Retained Earnings (Balance) -803.8m / Total Assets 964.0m |
| (C) -0.09 = EBIT TTM -85.7m / Avg Total Assets 941.6m |
| (D) -0.93 = Book Value of Equity -803.8m / Total Liabilities 860.4m |
| Total Rating: -0.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.84
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 0.48% = 0.24 |
| 3. FCF Margin 4.24% = 1.06 |
| 4. Debt/Equity 6.41 = -2.50 |
| 5. Debt/Ebitda -10.15 = -2.50 |
| 6. ROIC - WACC (= -20.24)% = -12.50 |
| 7. RoE -104.7% = -2.50 |
| 8. Rev. Trend 97.90% = 7.34 |
| 9. EPS Trend 23.91% = 1.20 |
What is the price of IRTC shares?
Over the past week, the price has changed by -5.41%, over one month by +9.04%, over three months by +18.80% and over the past year by +140.81%.
Is iRhythm Technologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRTC is around 167.00 USD . This means that IRTC is currently overvalued and has a potential downside of -3.02%.
Is IRTC a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IRTC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 182.6 | 6.1% |
| Analysts Target Price | 182.6 | 6.1% |
| ValueRay Target Price | 186.4 | 8.2% |
Last update: 2025-09-04 10:00
IRTC Fundamental Data Overview
CCE Cash And Equivalents = 545.5m USD (Cash And Short Term Investments, last quarter)
P/S = 8.6319
P/B = 54.7591
Beta = 1.407
Revenue TTM = 657.2m USD
EBIT TTM = -85.7m USD
EBITDA TTM = -65.4m USD
Long Term Debt = 648.0m USD (from longTermDebt, last quarter)
Short Term Debt = 16.4m USD (from shortTermDebt, last quarter)
Debt = 664.4m USD (Calculated: Short Term 16.4m + Long Term 648.0m)
Net Debt = 425.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.79b USD (5.67b + Debt 664.4m - CCE 545.5m)
Interest Coverage Ratio = -6.90 (Ebit TTM -85.7m / Interest Expense TTM 12.4m)
FCF Yield = 0.48% (FCF TTM 27.9m / Enterprise Value 5.79b)
FCF Margin = 4.24% (FCF TTM 27.9m / Revenue TTM 657.2m)
Net Margin = -14.06% (Net Income TTM -92.4m / Revenue TTM 657.2m)
Gross Margin = 69.78% ((Revenue TTM 657.2m - Cost of Revenue TTM 198.6m) / Revenue TTM)
Tobins Q-Ratio = -7.21 (set to none) (Enterprise Value 5.79b / Book Value Of Equity -803.8m)
Interest Expense / Debt = 0.38% (Interest Expense 2.51m / Debt 664.4m)
Taxrate = 21.0% (US default)
NOPAT = -85.7m (EBIT -85.7m, no tax applied on loss)
Current Ratio = 5.02 (Total Current Assets 663.9m / Total Current Liabilities 132.2m)
Debt / Equity = 6.41 (Debt 664.4m / last Quarter total Stockholder Equity 103.7m)
Debt / EBITDA = -10.15 (Net Debt 425.6m / EBITDA -65.4m)
Debt / FCF = 23.83 (Debt 664.4m / FCF TTM 27.9m)
Total Stockholder Equity = 88.2m (last 4 quarters mean)
RoA = -9.59% (Net Income -92.4m, Total Assets 964.0m )
RoE = -104.7% (Net Income TTM -92.4m / Total Stockholder Equity 88.2m)
RoCE = -11.64% (Ebit -85.7m / (Equity 88.2m + L.T.Debt 648.0m))
RoIC = -11.66% (NOPAT -85.7m / Invested Capital 735.1m)
WACC = 8.58% (E(5.67b)/V(6.34b) * Re(9.55%)) + (D(664.4m)/V(6.34b) * Rd(0.38%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 99.24 | Cagr: 0.45%
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 68.90% ; FCFE base≈27.9m ; Y1≈22.6m ; Y5≈15.7m
Fair Price DCF = 7.07 (DCF Value 227.2m / Shares Outstanding 32.1m; 5y FCF grow -22.83% → 3.0% )
EPS Correlation: 23.91 | EPS CAGR: 14.12% | SUE: 0.53 | # QB: 0
Revenue Correlation: 97.90 | Revenue CAGR: 23.76% | SUE: 4.0 | # QB: 2
Additional Sources for IRTC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle